Cartesian Therapeutics, Inc. - COMMON STOCK (RNAC)

Q3 2024 13F Holders as of 9/30/2024

Type / Class
Equity / COMMON STOCK
Shares outstanding
26M
Number of holders
61
Total 13F shares, excl. options
6.87M
Shares change
+3.01M
Total reported value, excl. options
$110M
Value change
+$42.9M
Number of buys
30
Number of sells
-20
Price
$16.12

Significant Holders of Cartesian Therapeutics, Inc. - COMMON STOCK (RNAC) as of Q3 2024

73 filings reported holding RNAC - Cartesian Therapeutics, Inc. - COMMON STOCK as of Q3 2024.
Cartesian Therapeutics, Inc. - COMMON STOCK (RNAC) has 61 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 6.87M shares of 26M outstanding shares and own 26.44% of the company stock.
Largest 10 shareholders include FMR LLC (2.85M shares), MPM BIOIMPACT LLC (629K shares), Siren, L.L.C. (572K shares), BlackRock, Inc. (423K shares), CITADEL ADVISORS LLC (376K shares), JPMORGAN CHASE & CO (309K shares), VANGUARD GROUP INC (243K shares), GREAT POINT PARTNERS LLC (200K shares), Erste Asset Management GmbH (174K shares), and STATE STREET CORP (157K shares).
This table shows the top 61 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.